NFKB1 and ovarian carcinoma: The strengths of this model are (i) the capacity to evaluate the role of NF-κB activity in mediating the link between cancer progression and the immune system in ovarian cancer, and (ii) the ability to measure NF-κB activity through a dual luciferase -GFP fusion protein, allowing multiple independent assays to confirm changes in NF-κB activity in living animals and in harvested tumors.